Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab

Published:2020-08 Issue:4 Volume:4 Page:460-463
ISSN:2542-4548
Container-title:Mayo Clinic Proceedings: Innovations, Quality & Outcomes
language:en
Short-container-title:Mayo Clinic Proceedings: Innovations, Quality & Outcomes

Author:

Albitar Hasan Ahmad^ORCID,Almodallal Yahya,Nishimura Rick,Iyer Vivek N.^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference15 articles.

1. Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding [published correction appears in Mayo Clin Proc. 2018;93(3):396];Iyer;Mayo Clin Proc,2018

2. High rates of bleeding complications among hospitalized patients with hereditary hemorrhagic telangiectasia in the United States;Brinjikji;Ann Am Thorac Soc,2016

3. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output;Dupuis-Girod;JAMA,2012

4. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia;Al-Samkari;J Intern Med,2019

5. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia;Buscarini;Orphanet J Rare Dis,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP